Tuesday, August 24, 2010 9:23:54 AM
This stock is on its way out, they do have some product on the market now, but this new treatment will not be allowed to move forward regardless of how hopefull and loud the investor community gets. Its just not going to happen. Target price 5.5-6 dollars within the week. get out now.
Recent JAZZ News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:09:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 08:01:41 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/29/2026 08:11:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2026 08:21:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2026 08:18:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 10:13:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 10:07:06 PM
- Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA • PR Newswire (US) • 05/27/2026 09:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 08:27:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 08:13:14 PM
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/12/2026 08:15:00 PM
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/12/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:06:23 PM
- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results • PR Newswire (US) • 05/05/2026 08:05:00 PM
- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results • PR Newswire (US) • 05/05/2026 08:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:19:10 PM
- Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA • PR Newswire (US) • 04/27/2026 11:45:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/24/2026 08:09:04 PM
- Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 • PR Newswire (US) • 04/21/2026 08:15:00 PM
- Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 • PR Newswire (US) • 04/21/2026 08:15:00 PM
- Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) • PR Newswire (US) • 04/21/2026 08:05:00 PM
- Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting • PR Newswire (US) • 04/09/2026 11:45:00 AM
- Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference • PR Newswire (US) • 04/01/2026 08:15:00 PM
- American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education • PR Newswire (US) • 03/24/2026 05:49:00 PM
